RTA Laboratuvarlari Biyolojik
Buy, Hold or Sell?
Let's analyze RTA Laboratuvarlari Biyolojik together
I guess you are interested in RTA Laboratuvarlari Biyolojik. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.
I'm going to help you getting a better view of RTA Laboratuvarlari Biyolojik. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.
Get notifications about RTA Laboratuvarlari Biyolojik
I send you an email if I find something interesting about RTA Laboratuvarlari Biyolojik.
1. Quick Overview
1.1. Quick analysis of RTA Laboratuvarlari Biyolojik (30 sec.)
1.2. What can you expect buying and holding a share of RTA Laboratuvarlari Biyolojik? (30 sec.)
How much money do you get?
What is your share worth?
+ What do you gain per year?
2. Detailed Analysis
2.1. Valuation of RTA Laboratuvarlari Biyolojik (5 min.)
2.2. Growth of RTA Laboratuvarlari Biyolojik (5 min.)
Is RTA Laboratuvarlari Biyolojik growing?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
How rich? | $18.6m | $10m | $8.5m | 45.8% |
How much money is RTA Laboratuvarlari Biyolojik making?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
Making money | $8.2m | $3.3m | $4.8m | 59.3% |
Net Profit Margin | 326.8% | 29.8% | - | - |
How much money comes from the company's main activities?
2.3. Financial Health of RTA Laboratuvarlari Biyolojik (5 min.)
2.4. Comparing to competitors in the Biotechnology industry (5 min.)
Industry Rankings (Biotechnology)
3. Summary and Key Metrics
3.1. What can you expect buying and holding a share of RTA Laboratuvarlari Biyolojik?
Welcome investor! RTA Laboratuvarlari Biyolojik's management wants to use your money to grow the business. In return you get a share of RTA Laboratuvarlari Biyolojik.
First you should know what it really means to hold a share of RTA Laboratuvarlari Biyolojik. And how you can make/lose money.
Speculation
The Price per Share of RTA Laboratuvarlari Biyolojik is ₺17.09. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.
If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:
- The fundamentals: the financial health trends of RTA Laboratuvarlari Biyolojik.
- The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
- The book value: what is the market price compared to it's book value.
Investing
If you really want to invest in RTA Laboratuvarlari Biyolojik, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:
- You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₺6.33. Based on the TTM, the Book Value Change Per Share is ₺2.90 per quarter. Based on the YOY, the Book Value Change Per Share is ₺1.75 per quarter.
- You may receive quarterly/yearly dividend in the form of additional shares.
- You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₺0.00 per quarter.
How much money are you going to get?
MRQ | TTM | YOY | 5Y | 10Y | ||||||
---|---|---|---|---|---|---|---|---|---|---|
₺ | % of Price per Share | ₺ | % of Price per Share | ₺ | % of Price per Share | ₺ | % of Price per Share | ₺ | % of Price per Share | |
Usd Eps | 0.08 | 0.5% | 0.08 | 0.5% | 0.03 | 0.2% | 0.03 | 0.2% | 0.01 | 0.1% |
Usd Book Value Change Per Share | 0.09 | 0.5% | 0.09 | 0.5% | 0.05 | 0.3% | 0.03 | 0.2% | 0.02 | 0.1% |
Usd Dividend Per Share | 0.00 | 0.0% | 0.00 | 0.0% | 0.00 | 0.0% | 0.00 | 0.0% | 0.00 | 0.0% |
Usd Total Gains Per Share | 0.09 | 0.5% | 0.09 | 0.5% | 0.05 | 0.3% | 0.03 | 0.2% | 0.02 | 0.1% |
Usd Price Per Share | 0.38 | - | 0.38 | - | 0.65 | - | 0.41 | - | 0.30 | - |
Price to Earnings Ratio | 4.62 | - | 4.62 | - | 19.34 | - | 41.05 | - | 83.46 | - |
Price-to-Total Gains Ratio | 4.49 | - | 4.49 | - | 12.62 | - | 24.83 | - | 67.52 | - |
Price to Book Ratio | 2.05 | - | 2.05 | - | 6.45 | - | 6.45 | - | 10.36 | - |
Price-to-Total Gains Ratio | 4.49 | - | 4.49 | - | 12.62 | - | 24.83 | - | 67.52 | - |
When do you get the money?
Usd Investment | |
---|---|
Usd Price Per Share | 0.502446 |
Number of shares | 1990 |
Gains per Quarter | Trailing 12 Months | 5 Year |
---|---|---|
Usd Dividend Per Share | 0.00 | 0.00 |
Usd Book Value Change Per Share | 0.09 | 0.03 |
Usd Total Gains Per Share | 0.09 | 0.03 |
Gains per Quarter (1990 shares) | 169.38 | 67.69 |
Gains per Year (1990 shares) | 677.51 | 270.76 |
Years | Return on Investment (TTM) | Return on Investment (5Y) | ||||
---|---|---|---|---|---|---|
Dividend | Book Value gain | Total gains | Dividend | Book Value gain | Total gains | |
Broker costs | - | - | -10 | - | - | -10 |
1 | 0 | 678 | 668 | 0 | 271 | 261 |
2 | 0 | 1355 | 1346 | 0 | 542 | 532 |
3 | 0 | 2033 | 2024 | 0 | 812 | 803 |
4 | 0 | 2710 | 2702 | 0 | 1083 | 1074 |
5 | 0 | 3388 | 3380 | 0 | 1354 | 1345 |
6 | 0 | 4065 | 4058 | 0 | 1625 | 1616 |
7 | 0 | 4743 | 4736 | 0 | 1895 | 1887 |
8 | 0 | 5420 | 5414 | 0 | 2166 | 2158 |
9 | 0 | 6098 | 6092 | 0 | 2437 | 2429 |
10 | 0 | 6775 | 6770 | 0 | 2708 | 2700 |
How sure are you?
Based on the past periods, how sure are you to get value out of your investment.
Linear %
Trailing 12 Months | 3Y | 5 Year | 10 Year | ALLTIME | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% | % | % | % | % | ||||||||||||||||
Earnings Per Share | 1.0 | 0.0 | 0.0 | 100.0% | 3.0 | 0.0 | 0.0 | 100.0% | 5.0 | 0.0 | 0.0 | 100.0% | 9.0 | 0.0 | 1.0 | 90.0% | 9.0 | 0.0 | 4.0 | 69.2% |
Book Value Change Per Share | 1.0 | 0.0 | 0.0 | 100.0% | 3.0 | 0.0 | 0.0 | 100.0% | 5.0 | 0.0 | 0.0 | 100.0% | 10.0 | 0.0 | 0.0 | 100.0% | 12.0 | 1.0 | 0.0 | 92.3% |
Dividend per Share | 0.0 | 0.0 | 1.0 | 0.0% | 0.0 | 0.0 | 3.0 | 0.0% | 0.0 | 0.0 | 5.0 | 0.0% | 0.0 | 0.0 | 10.0 | 0.0% | 3.0 | 0.0 | 10.0 | 23.1% |
Total Gains per Share | 1.0 | 0.0 | 0.0 | 100.0% | 3.0 | 0.0 | 0.0 | 100.0% | 5.0 | 0.0 | 0.0 | 100.0% | 10.0 | 0.0 | 0.0 | 100.0% | 13.0 | 0.0 | 0.0 | 100.0% |
3.2. Key Performance Indicators
The key performance indicators of RTA Laboratuvarlari Biyolojik compared to the Most Recent Quarter (MRQ).
End of day | +/- | Most Recent Quarter | Trailing 12 Months | +/- | Year-Over-Year | +/- | 5 Year | +/- | 10 Year | +/- | |
---|---|---|---|---|---|---|---|---|---|---|---|
Book Value Change Per Share | - | - | 2.895 | 2.895 | 0% | 1.754 | +65% | 1.157 | +150% | 0.622 | +366% |
Book Value Per Share | - | - | 6.327 | 6.327 | 0% | 3.432 | +84% | 2.575 | +146% | 1.497 | +323% |
Current Ratio | - | - | 3.393 | 3.393 | 0% | 1.803 | +88% | 3.263 | +4% | 3.295 | +3% |
Debt To Asset Ratio | - | - | 0.145 | 0.145 | 0% | 0.379 | -62% | 0.225 | -35% | 0.220 | -34% |
Debt To Equity Ratio | - | - | 0.181 | 0.181 | 0% | 0.669 | -73% | 0.346 | -48% | 0.315 | -43% |
Dividend Per Share | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Eps | - | - | 2.811 | 2.811 | 0% | 1.145 | +146% | 0.926 | +203% | 0.483 | +482% |
Free Cash Flow Per Share | - | - | -1.535 | -1.535 | 0% | 0.470 | -427% | -0.248 | -84% | -0.114 | -93% |
Free Cash Flow To Equity Per Share | - | - | -1.505 | -1.505 | 0% | 1.229 | -222% | -0.005 | -100% | 0.022 | -6992% |
Gross Profit Margin | - | - | 1.000 | 1.000 | 0% | 1.000 | 0% | 1.000 | 0% | 0.900 | +11% |
Intrinsic Value_10Y_max | - | - | -5.046 | - | - | - | - | - | - | - | - |
Intrinsic Value_10Y_min | - | - | -14.031 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_max | - | - | -0.199 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_min | - | - | -0.645 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_max | - | - | -0.832 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_min | - | - | -2.609 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_max | - | - | -1.746 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_min | - | - | -5.292 | - | - | - | - | - | - | - | - |
Market Cap | 1709000000.000 | +24% | 1299000000.000 | 1299000000.000 | 0% | 2214000000.000 | -41% | 1389400000.000 | -7% | 1014202000.000 | +28% |
Net Profit Margin | - | - | 3.268 | 3.268 | 0% | 0.298 | +997% | 0.825 | +296% | 0.475 | +587% |
Operating Margin | - | - | -0.091 | -0.091 | 0% | 0.247 | -137% | -0.053 | -41% | 0.036 | -351% |
Operating Ratio | - | - | 1.686 | 1.686 | 0% | 1.341 | +26% | 1.673 | +1% | 1.468 | +15% |
Pb Ratio | 2.701 | +24% | 2.053 | 2.053 | 0% | 6.450 | -68% | 6.455 | -68% | 10.363 | -80% |
Pe Ratio | 6.079 | +24% | 4.621 | 4.621 | 0% | 19.341 | -76% | 41.045 | -89% | 83.459 | -94% |
Price Per Share | 17.090 | +24% | 12.990 | 12.990 | 0% | 22.140 | -41% | 13.894 | -7% | 10.142 | +28% |
Price To Free Cash Flow Ratio | -11.130 | -32% | -8.460 | -8.460 | 0% | 47.129 | -118% | -108.737 | +1185% | 230.515 | -104% |
Price To Total Gains Ratio | 5.903 | +24% | 4.487 | 4.487 | 0% | 12.621 | -64% | 24.830 | -82% | 67.519 | -93% |
Quick Ratio | - | - | 2.260 | 2.260 | 0% | 0.535 | +323% | 1.718 | +32% | 1.439 | +57% |
Return On Assets | - | - | 0.380 | 0.380 | 0% | 0.207 | +83% | 0.176 | +116% | 0.123 | +210% |
Return On Equity | - | - | 0.473 | 0.473 | 0% | 0.366 | +29% | 0.261 | +81% | 0.175 | +170% |
Total Gains Per Share | - | - | 2.895 | 2.895 | 0% | 1.754 | +65% | 1.157 | +150% | 0.622 | +366% |
Usd Book Value | - | - | 18602549.120 | 18602549.120 | 0% | 10091087.773 | +84% | 7570717.178 | +146% | 4401772.339 | +323% |
Usd Book Value Change Per Share | - | - | 0.085 | 0.085 | 0% | 0.052 | +65% | 0.034 | +150% | 0.018 | +366% |
Usd Book Value Per Share | - | - | 0.186 | 0.186 | 0% | 0.101 | +84% | 0.076 | +146% | 0.044 | +323% |
Usd Dividend Per Share | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Usd Eps | - | - | 0.083 | 0.083 | 0% | 0.034 | +146% | 0.027 | +203% | 0.014 | +482% |
Usd Free Cash Flow | - | - | -4514346.274 | -4514346.274 | 0% | 1381135.589 | -427% | -728223.335 | -84% | -335679.616 | -93% |
Usd Free Cash Flow Per Share | - | - | -0.045 | -0.045 | 0% | 0.014 | -427% | -0.007 | -84% | -0.003 | -93% |
Usd Free Cash Flow To Equity Per Share | - | - | -0.044 | -0.044 | 0% | 0.036 | -222% | 0.000 | -100% | 0.001 | -6992% |
Usd Market Cap | 50244600.000 | +24% | 38190600.000 | 38190600.000 | 0% | 65091600.000 | -41% | 40848360.000 | -7% | 29817538.800 | +28% |
Usd Price Per Share | 0.502 | +24% | 0.382 | 0.382 | 0% | 0.651 | -41% | 0.408 | -7% | 0.298 | +28% |
Usd Profit | - | - | 8264839.976 | 8264839.976 | 0% | 3365525.839 | +146% | 2713902.087 | +205% | 1416532.895 | +483% |
Usd Revenue | - | - | 2529164.047 | 2529164.047 | 0% | 11299644.245 | -78% | 4339724.592 | -42% | 2608044.356 | -3% |
Usd Total Gains Per Share | - | - | 0.085 | 0.085 | 0% | 0.052 | +65% | 0.034 | +150% | 0.018 | +366% |
EOD | +5 -3 | MRQ | TTM | +0 -0 | YOY | +21 -12 | 5Y | +20 -13 | 10Y | +24 -10 |
3.3 Fundamental Score
Penke's Stock Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Price to Earnings Ratio (EOD) | Between | 0-15 | 6.079 | |
Price to Book Ratio (EOD) | Between | 0-1 | 2.701 | |
Net Profit Margin (MRQ) | Greater than | 0 | 3.268 | |
Operating Margin (MRQ) | Greater than | 0 | -0.091 | |
Quick Ratio (MRQ) | Greater than | 1 | 2.260 | |
Current Ratio (MRQ) | Greater than | 1 | 3.393 | |
Debt to Asset Ratio (MRQ) | Less than | 1 | 0.145 | |
Debt to Equity Ratio (MRQ) | Less than | 1 | 0.181 | |
Return on Equity (MRQ) | Greater than | 0.15 | 0.473 | |
Return on Assets (MRQ) | Greater than | 0.05 | 0.380 | |
Total | 8/10 (80.0%) |
3.4 Technical Score
Penke's Symbol Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Rsi | Greater than | 50 | 43.643 | |
Ma 20 | Greater than | Ma 50 | 21.945 | |
Ma 50 | Greater than | Ma 100 | 16.145 | |
Ma 100 | Greater than | Ma 200 | 14.127 | |
Open | Greater than | Close | 16.730 | |
Total | 2/5 (40.0%) |
4. In-depth Analysis
4.1 About RTA Laboratuvarlari Biyolojik
- https://www.rtalabs.com.tr
- Biotechnology
- 56
- PlastikCiler Organize Sanayi BOelgesi (G, Kocaeli, Turkey, 41400
Google Maps Bing Maps
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. engages in the research, development, and production of microbiology and molecular biology products in Turkey. It offers microbiology products, including petri dish, tube and bottle, chromogenic media, blood culture bottle, tuberculosis diagnostic, rapid test, microbiological stain, hygislide, surcheck media, membrane, and swab products; and molecular biology products, such as nucleic acid isolation kits, real time PCR kits, and voltran viral load detection systems. The company was incorporated in 1996 and is based in Kocaeli, Turkey.
Fundamental data was last updated by Penke on 2024-09-03 21:49:03.
4.2 In-depth Summary
4.2.1. Financial Health Summary
Compared to previous year | Compared to industry | |
---|---|---|
The company is making a huge profit. | ||
Using its assets, the company is very efficient in making profit. | ||
Using its investors money, the company is very efficient in making profit. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is operating very inefficient. | ||
The company is inefficient in keeping operating costs low. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is very able to pay all its short-term debts. | ||
The company is very able to pay all its short-term debts with the most liquid assets. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is very able to pay all its debts by selling its assets. | ||
The company is very able to pay all its debts with equity. |
4.2.2. Valuation Summary
Compared to previous year | Compared to industry | |
---|---|---|
Based on the equity, the company is underpriced. | ||
Based on the earnings, the company is cheap. | ||
Based on how much money comes from the company's main activities, the company is expensive. |
4.3 Financial Health
4.3.1. Profitability
4.3.1 Profitability
4.3.1.1. Net Profit Margin
- Above 10% is considered healthy but always compare RTA Laboratuvarlari Biyolojik to the Biotechnology industry mean.
- A Net Profit Margin of 326.8% means that ₤3.27 for each ₤1 in revenue is generated as profit.
Let's take a look of the Net Profit Margin trends of RTA Laboratuvarlari Biyolojik:
Trends
- The YOY is 29.8%. Compared to the TTM, the mid term is trending up. +2
- The 5Y is 82.5%. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is 47.5%. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 326.8% | TTM | 326.8% | 0.0% | |
TTM | 326.8% | YOY | 29.8% | +297.0% | |
TTM | 326.8% | 5Y | 82.5% | +244.3% | |
5Y | 82.5% | 10Y | 47.5% | +34.9% |
Compared to industry (Biotechnology)
Let compare the company's Net Profit Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -131.4%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -212.1%. trending up. +2
4.3.1.2. Return on Assets
- Above 5% is considered healthy but always compare RTA Laboratuvarlari Biyolojik to the Biotechnology industry mean.
- 38.0% Return on Assets means that RTA Laboratuvarlari Biyolojik generated ₤0.38 profit for each $1 in assets.
Let's take a look of the Return on Assets trends of RTA Laboratuvarlari Biyolojik:
Trends
- The YOY is 20.7%. Compared to the TTM, the mid term is trending up. +2
- The 5Y is 17.6%. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is 12.3%. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 38.0% | TTM | 38.0% | 0.0% | |
TTM | 38.0% | YOY | 20.7% | +17.3% | |
TTM | 38.0% | 5Y | 17.6% | +20.4% | |
5Y | 17.6% | 10Y | 12.3% | +5.3% |
Compared to industry (Biotechnology)
Let compare the company's Return on Assets with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -11.0%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -11.8%. trending up. +2
4.3.1.3. Return on Equity
- Above 15%-20% is considered healthy but always compare RTA Laboratuvarlari Biyolojik to the Biotechnology industry mean.
- 47.3% Return on Equity means RTA Laboratuvarlari Biyolojik generated ₤0.47 for each ₤1 the owners (shareholders) invested.
Let's take a look of the Return on Equity trends of RTA Laboratuvarlari Biyolojik:
Trends
- The YOY is 36.6%. Compared to the TTM, the mid term is trending up. +2
- The 5Y is 26.1%. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is 17.5%. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 47.3% | TTM | 47.3% | 0.0% | |
TTM | 47.3% | YOY | 36.6% | +10.7% | |
TTM | 47.3% | 5Y | 26.1% | +21.2% | |
5Y | 26.1% | 10Y | 17.5% | +8.6% |
Compared to industry (Biotechnology)
Let compare the company's Return on Equity with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -13.8%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -16.1%. trending up. +2
4.3.2. Operating Efficiency of RTA Laboratuvarlari Biyolojik.
4.3.2. Operating Efficiency
4.3.2.1. Operating Margin
- Measures how much profit RTA Laboratuvarlari Biyolojik makes for each ₤1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
- Above 15% is considered healthy but always compare RTA Laboratuvarlari Biyolojik to the Biotechnology industry mean.
- An Operating Margin of -9.1% means the company generated ₤-0.09 for each ₤1 in revenue (before taxes).
Let's take a look of the Operating Margin trends of RTA Laboratuvarlari Biyolojik:
Trends
- The YOY is 24.7%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -5.3%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 3.6%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -9.1% | TTM | -9.1% | 0.0% | |
TTM | -9.1% | YOY | 24.7% | -33.7% | |
TTM | -9.1% | 5Y | -5.3% | -3.7% | |
5Y | -5.3% | 10Y | 3.6% | -8.9% |
Compared to industry (Biotechnology)
Let compare the company's Operating Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -286.0%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -305.1%. trending up. +2
4.3.2.2. Operating Ratio
- Below 1 is considered healthy (always compare to Biotechnology industry mean).
- An Operation Ratio of 1.69 means that the operating costs are ₤1.69 for each ₤1 in net sales.
Let's take a look of the Operating Ratio trends of RTA Laboratuvarlari Biyolojik:
Trends
- The YOY is 1.341. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 1.673. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 1.468. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 1.686 | TTM | 1.686 | 0.000 | |
TTM | 1.686 | YOY | 1.341 | +0.345 | |
TTM | 1.686 | 5Y | 1.673 | +0.013 | |
5Y | 1.673 | 10Y | 1.468 | +0.205 |
Compared to industry (Biotechnology)
Let compare the company's Operating Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 2.760. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 3.284. trending down. +2
4.4.3. Liquidity of RTA Laboratuvarlari Biyolojik.
4.4.3. Liquidity
4.4.3.1. Current Ratio
- Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
- A Current Ratio of 3.39 means the company has ₤3.39 in assets for each ₤1 in short-term debts.
Let's take a look of the Current Ratio trends of RTA Laboratuvarlari Biyolojik:
Trends
- The YOY is 1.803. Compared to the TTM, the mid term is trending up. +2
- The 5Y is 3.263. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is 3.295. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 3.393 | TTM | 3.393 | 0.000 | |
TTM | 3.393 | YOY | 1.803 | +1.590 | |
TTM | 3.393 | 5Y | 3.263 | +0.130 | |
5Y | 3.263 | 10Y | 3.295 | -0.032 |
Compared to industry (Biotechnology)
Let compare the company's Current Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.740. trending down. -2
- The TTM average (mean) in the Biotechnology industry is 3.919. trending down. -2
4.4.3.2. Quick Ratio
- Above 1 is considered healthy but always compare RTA Laboratuvarlari Biyolojik to the Biotechnology industry mean.
- A Quick Ratio of 2.26 means the company can pay off ₤2.26 for each ₤1 in debt (using most liquid assets).
Let's take a look of the Quick Ratio trends of RTA Laboratuvarlari Biyolojik:
Trends
- The YOY is 0.535. Compared to the TTM, the mid term is trending up. +2
- The 5Y is 1.718. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is 1.439. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 2.260 | TTM | 2.260 | 0.000 | |
TTM | 2.260 | YOY | 0.535 | +1.726 | |
TTM | 2.260 | 5Y | 1.718 | +0.542 | |
5Y | 1.718 | 10Y | 1.439 | +0.280 |
Compared to industry (Biotechnology)
Let compare the company's Quick Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.138. trending down. -2
- The TTM average (mean) in the Biotechnology industry is 3.448. trending down. -2
4.5.4. Solvency of RTA Laboratuvarlari Biyolojik.
4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio
- Below 1 (100%) is considered healthy but always compare RTA Laboratuvarlari Biyolojik to Biotechnology industry mean.
- A Debt to Asset Ratio of 0.15 means that RTA Laboratuvarlari Biyolojik assets are financed with 14.5% credit (debt) and the remaining percentage (100% - 14.5%) is financed by its owners/shareholders.
Let's take a look of the Debt to Asset Ratio trends of RTA Laboratuvarlari Biyolojik:
Trends
- The YOY is 0.379. Compared to the TTM, the mid term is trending down. +2
- The 5Y is 0.225. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 0.220. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.145 | TTM | 0.145 | 0.000 | |
TTM | 0.145 | YOY | 0.379 | -0.233 | |
TTM | 0.145 | 5Y | 0.225 | -0.079 | |
5Y | 0.225 | 10Y | 0.220 | +0.004 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Asset Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.342. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 0.345. trending down. +2
4.5.4.2. Debt to Equity Ratio
- Below 2 is considered healthy but always compare RTA Laboratuvarlari Biyolojik to the Biotechnology industry mean.
- A Debt to Equity ratio of 18.1% means that company has ₤0.18 debt for each ₤1 in shareholders equity.
Let's take a look of the Debt to Equity Ratio trends of RTA Laboratuvarlari Biyolojik:
Trends
- The YOY is 0.669. Compared to the TTM, the mid term is trending down. +2
- The 5Y is 0.346. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 0.315. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.181 | TTM | 0.181 | 0.000 | |
TTM | 0.181 | YOY | 0.669 | -0.488 | |
TTM | 0.181 | 5Y | 0.346 | -0.165 | |
5Y | 0.346 | 10Y | 0.315 | +0.031 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Equity Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.394. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 0.450. trending down. +2
4.6. Market Valuation
4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio
- Above 15 is considered overpriced but always compare RTA Laboratuvarlari Biyolojik to the Biotechnology industry mean.
- A PE ratio of 4.62 means the investor is paying ₤4.62 for every ₤1 in earnings.
Let's take a look of the Price to Earnings Ratio trends of RTA Laboratuvarlari Biyolojik:
Trends
- The YOY is 19.341. Compared to the TTM, the mid term is trending down. +2
- The 5Y is 41.045. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 83.459. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | 6.079 | MRQ | 4.621 | +1.458 | |
MRQ | 4.621 | TTM | 4.621 | 0.000 | |
TTM | 4.621 | YOY | 19.341 | -14.720 | |
TTM | 4.621 | 5Y | 41.045 | -36.424 | |
5Y | 41.045 | 10Y | 83.459 | -42.414 |
Compared to industry (Biotechnology)
Let compare the company's Price to Earnings Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -2.392. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -2.971. trending up. +2
4.6.2.2. Price To Free Cash Flow Ratio
Let's take a look of the Price To Free Cash Flow Ratio trends of RTA Laboratuvarlari Biyolojik:
- The EOD is -11.130. Based on how much money comes from the company's main activities, the company is expensive. -2
- The MRQ is -8.460. Based on how much money comes from the company's main activities, the company is expensive. -2
- The TTM is -8.460. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
- The YOY is 47.129. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -108.737. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 230.515. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | -11.130 | MRQ | -8.460 | -2.670 | |
MRQ | -8.460 | TTM | -8.460 | 0.000 | |
TTM | -8.460 | YOY | 47.129 | -55.589 | |
TTM | -8.460 | 5Y | -108.737 | +100.277 | |
5Y | -108.737 | 10Y | 230.515 | -339.251 |
Compared to industry (Biotechnology)
Let compare the company's priceToFreeCashFlowRatio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -3.198. trending down. +2
- The TTM average (mean) in the Biotechnology industry is -3.575. trending down. +2
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio
- At or below 1 is considered healthy (always compare to Biotechnology industry mean).
- A PB ratio of 2.05 means the investor is paying ₤2.05 for each ₤1 in book value.
Let's take a look of the Price to Book Ratio trends of RTA Laboratuvarlari Biyolojik:
Trends
- The YOY is 6.450. Compared to the TTM, the mid term is trending down. +2
- The 5Y is 6.455. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 10.363. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | 2.701 | MRQ | 2.053 | +0.648 | |
MRQ | 2.053 | TTM | 2.053 | 0.000 | |
TTM | 2.053 | YOY | 6.450 | -4.397 | |
TTM | 2.053 | 5Y | 6.455 | -4.402 | |
5Y | 6.455 | 10Y | 10.363 | -3.908 |
Compared to industry (Biotechnology)
Let compare the company's Price to Book Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 1.903. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 2.210. trending down. +2
4.6.2. Total Gains per Share
6. Financial Statements
6.1. Latest Balance Sheet
Balance Sheet of 2022-12-31. Currency in TRY. All numbers in thousands.
Summary
As reported | |
---|---|
Total Liabilities | 107,473 |
Total Stockholder Equity | + 594,521 |
Total Assets | = 740,213 |
Assets
Total Current Assets
Long-term Assets
Property Plant Equipment | 53,680 |
Intangible Assets | 449 |
Other Assets | 11,663 |
Long-term Assets (as reported) | 439,682 |
---|---|
Long-term Assets (calculated) | 65,792 |
+/- | 373,890 |
Liabilities & Shareholders' Equity
Total Current Liabilities
Long-term Liabilities
Long term Debt | 1,577 |
Capital Lease Obligations Min Short Term Debt | 1,183 |
Other Liabilities | 16,489 |
Long-term Liabilities (as reported) | 18,888 |
---|---|
Long-term Liabilities (calculated) | 19,249 |
+/- | 361 |
Total Stockholder Equity
Common Stock | 100,000 |
Retained Earnings | 463,841 |
Other Stockholders Equity | 8,865 |
Total Stockholder Equity (as reported) | 594,521 |
---|---|
Total Stockholder Equity (calculated) | 572,706 |
+/- | 21,815 |
Other
Capital Stock | 100,000 |
Common Stock Shares Outstanding | 100,000 |
Net Debt | 37,290 |
Net Invested Capital | 663,174 |
Net Tangible Assets | 594,072 |
Net Working Capital | 212,336 |
Property Plant and Equipment Gross | 71,209 |
6.2. Balance Sheets Structured
Currency in TRY. All numbers in thousands.
Trend | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
> Total Assets |
| 740,213 | 552,404 | 256,525 | 98,160 | 66,052 | 63,092 | 60,893 | 61,614 | 49,042 | 29,352 | 20,450 | 16,604 | 16,857 | |||||||||||||
> Total Current Assets |
| 300,531 | 369,387 | 142,975 | 34,561 | 32,864 | 40,847 | 37,436 | 38,662 | 36,222 | 0 | 0 | 0 | 0 | |||||||||||||
Cash And Cash Equivalents |
| 31,363 | 157,539 | 15,662 | 12,379 | 6,141 | 15,124 | 13,790 | 15,736 | 18,570 | 3,246 | 2,745 | 2,913 | 5,472 | |||||||||||||
Short-term Investments |
| 118,082 | 5,863 | 917 | 0 | 51 | 1,697 | 1,735 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||
Net Receivables |
| 82,133 | 103,661 | 73,833 | 16,310 | 18,515 | 14,865 | 9,872 | 9,364 | 7,847 | 5,501 | 7,204 | 4,649 | 4,575 | |||||||||||||
Other Current Assets |
| 30,309 | 41,830 | 21,661 | 2,763 | 3,984 | 1,390 | 2,053 | 2,742 | 1,419 | 808 | 863 | 628 | 512 | |||||||||||||
> Long-term Assets |
| 439,682 | 183,017 | 113,550 | 63,600 | 33,188 | 22,244 | 23,457 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||
Property Plant Equipment |
| 53,680 | 46,754 | 31,399 | 14,781 | 11,167 | 9,482 | 11,616 | 10,062 | 8,246 | 8,061 | 3,237 | 1,836 | 2,191 | |||||||||||||
Goodwill |
| 0 | 0 | 0 | 0 | 1,031 | 1,031 | 1,031 | 1,031 | 0 | 0 | 0 | 0 | 0 | |||||||||||||
Long Term Investments |
| 0 | 0 | 0 | 28,193 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||
Intangible Assets |
| 449 | 564 | 760 | 477 | 687 | 1,011 | 53 | 158 | 680 | 808 | 1,127 | 1,047 | 357 | |||||||||||||
Long-term Assets Other |
| 0 | 0 | 0 | 63,600 | 33,188 | 22,244 | 23,457 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||
> Total Liabilities |
| 107,473 | 209,170 | 88,719 | 11,466 | 8,990 | 8,841 | 10,690 | 14,878 | 11,399 | 8,519 | 9,459 | 6,412 | 5,393 | |||||||||||||
> Total Current Liabilities |
| 88,585 | 204,880 | 82,514 | 7,808 | 6,625 | 8,264 | 9,278 | 9,831 | 9,725 | 7,043 | 8,963 | 6,062 | 4,987 | |||||||||||||
Short-term Debt |
| 0 | 0 | 0 | 6,109 | 637 | 1,595 | 1,321 | 3,470 | 254 | 0 | 0 | 0 | 0 | |||||||||||||
Short Long Term Debt |
| 67,076 | 55,121 | 21,910 | 6,109 | 637 | 1,595 | 1,321 | 3,470 | 254 | 0 | 0 | 0 | 0 | |||||||||||||
Accounts payable |
| 11,149 | 101,272 | 23,557 | 1,438 | 5,260 | 4,862 | 5,902 | 7,224 | 7,573 | 5,530 | 5,234 | 3,894 | 2,254 | |||||||||||||
Other Current Liabilities |
| 8,796 | 45,750 | 29,922 | 83 | 113 | 1,667 | 1,519 | 2,181 | 1,898 | 1,505 | 2,412 | 1,176 | 1,791 | |||||||||||||
> Long-term Liabilities |
| 18,888 | 4,289 | 6,204 | 3,657 | 330 | 578 | 1,412 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||
Capital Lease Obligations Min Short Term Debt |
| 1,183 | 528 | 985 | -6,109 | -637 | -1,595 | -1,319 | -3,470 | -254 | 0 | 0 | 0 | 0 | |||||||||||||
Deferred Long Term Liability |
| 0 | 0 | 104 | 357 | 630 | 954 | 0 | 646 | 0 | 0 | 0 | 0 | 0 | |||||||||||||
> Total Stockholder Equity |
| 594,521 | 312,674 | 150,275 | 86,628 | 57,912 | 54,171 | 49,922 | 45,922 | 36,726 | 20,833 | 11,875 | 10,991 | 11,848 | |||||||||||||
Common Stock |
| 100,000 | 42,970 | 41,000 | 36,100 | 23,600 | 23,600 | 5,900 | 5,900 | 5,900 | 4,800 | 4,800 | 4,800 | 4,800 | |||||||||||||
Retained Earnings |
| 463,841 | 207,634 | 93,161 | 32,228 | 27,774 | 25,618 | 26,902 | 22,780 | 16,183 | 11,575 | 6,031 | 4,454 | 5,699 | |||||||||||||
Capital Surplus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | -94 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other Stockholders Equity |
| 8,865 | 9,192 | 9,183 | 18,230 | 8,161 | 4,952 | 5,087 | 5,115 | 2,516 | 0 | 0 | 0 | 0 |
6.3. Balance Sheets
Currency in TRY. All numbers in thousands.
6.4. Cash Flows
Currency in TRY. All numbers in thousands.
6.5. Income Statements
Currency in TRY. All numbers in thousands.
6.6. Latest Income Statement
Income Statement (annual), 2023-12-31. Currency in TRY. All numbers in thousands.
Gross Profit (+$) | ||
---|---|---|
totalRevenue | 52,558 | |
Cost of Revenue | -40,946 | |
Gross Profit | 11,612 | 11,612 |
Operating Income (+$) | ||
Gross Profit | 11,612 | |
Operating Expense | -67,490 | |
Operating Income | -14,932 | -55,877 |
Operating Expense (+$) | ||
Research Development | 7,635 | |
Selling General Administrative | 10,150 | |
Selling And Marketing Expenses | - | |
Operating Expense | 67,490 | 17,785 |
Net Interest Income (+$) | ||
Interest Income | 15,938 | |
Interest Expense | -15,472 | |
Other Finance Cost | -31,948 | |
Net Interest Income | -31,482 | |
Pretax Income (+$) | ||
Operating Income | -14,932 | |
Net Interest Income | -31,482 | |
Other Non-Operating Income Expenses | - | |
Income Before Tax (EBT) | 262,488 | -14,932 EBIT - interestExpense = -15,472 249,437 264,909 |
Interest Expense | 15,472 | |
Earnings Before Interest and Taxes (EBIT) | - | 277,960 |
Earnings Before Interest and Taxes (EBITDA) | - | |
After tax Income (+$) | ||
Income Before Tax | 262,488 | |
Tax Provision | -13,112 | |
Net Income From Continuing Ops | 249,376 | 249,376 |
Net Income | 249,437 | |
Net Income Applicable To Common Shares | - | |
Non-recurring Events | ||
Discontinued Operations | - | |
Extraordinary Items | - | |
Effect of Accounting Charges | - | |
Other Items | - | |
Non Recurring | - | |
Other Operating Expenses | - | |
Total Other Income/Expenses Net | - | 31,482 |
Technical Analysis of RTA Laboratuvarlari Biyolojik
The psychology behind the price
Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.
General trend
First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of RTA Laboratuvarlari Biyolojik. The general trend of RTA Laboratuvarlari Biyolojik is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine RTA Laboratuvarlari Biyolojik's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.
Indicator phases
Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:
Indicator zone transitions | Bullish trend (71.4%) | Bearish trend (-71.4%) | |
---|---|---|---|
Overbought to neutral | Bullish pullback | = | Bearish reversal |
Upper to lower neutral | Bullish correction | = | Bearish continuation |
Nuetral to oversold | Oversold | = | Oversold |
Oversold to neutral | Bullish reversal | = | Bearish correction |
Lower to upper neutral | Bullish continuation | = | Bearish pullback |
Nuetral to overbought | Overbought | = | Overbought |
1. Price Targets
1.1 Support & Resistance
Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.
Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.
Score
Let's take a look at the Support & Resistance of RTA Laboratuvarlari Biyolojik.
The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).
- Between support/resistance: The price is trading between support and resistance lines.
The bullish price targets are: 32.56.
The bearish price targets are: 13.96 > 13.57 > 13.42.
Tweet this2. Trend Indicators
2.1 Moving Averages
- Moving averages are lagging trend indicators.
- There are many types of moving averages.
- Moving averages are also used within other indicators.
Score
Let's take a look at the Moving Averages of RTA Laboratuvarlari Biyolojik. The current mas is .
The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).
- MA 20 trending up: The MA 20 is trending up. +1
- Close < MA 20: The price is below the MA 20. -1
- MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
- MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
- MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
- MA 50 trending up: The MA 50 is trending up. +1
- Close > MA 50: The price is above the MA 50. +1
- MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
- MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
- MA 100 trending up: The MA 100 is trending up. +1
- Close > MA 100: The price is above the MA 100. +1
- MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
- MA 200 trending up: The MA 200 is trending up. +1
- Close > MA 200: The price is above the MA 200. +1
Directionalities and relatives.
Moving Average | Amount of candles | Trend | Price +/- | vs. MA 50 | vs. MA 100 | vs. MA 200 |
---|---|---|---|---|---|---|
MA 20 | 20 | |||||
MA 50 | 50 | - | ||||
MA 100 | 100 | - | - | |||
MA 200 | 200 | - | - | - |
Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I
2.2 Moving Average Convergence/Divergence (MACD)
- MACD is a lagging momentum indicator.
- Uses two moving averages.
- Can show buy or sell signals based on momentum.
- Can show overbought. and oversold. levels.
Score
Let's take a look at the Moving Average Convergence/Divergence (MACD) of RTA Laboratuvarlari Biyolojik. The current macd is 0.51876016.
The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).
- MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the RTA Laboratuvarlari Biyolojik price going down in the near term. -2
- MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for RTA Laboratuvarlari Biyolojik. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the RTA Laboratuvarlari Biyolojik price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
- Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
2.3 Directional Movement Index (DMI)
The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.
Score
Let's take a look at the Directional Movement Index (DMI) of RTA Laboratuvarlari Biyolojik. The current adx is 40.62.
The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).
- PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy RTA Laboratuvarlari Biyolojik shares, leading to potential upward momentum in its price. +1
- PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
2.4 Parabolic SAR
- Parabolic SAR (stop and reverse) is a lagging trend indicator.
- Shows the current trend.
- Shows potential entry signals.
- Shows potential exit signals.
- Can be used to place trailing stoplosses..
Score
Let's take a look at the Parabolic SAR of RTA Laboratuvarlari Biyolojik. The current sar is 23.99.
The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).
- Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
3. Momentum Indicators
3.1 Relative Strength Index (RSI)
- Leading momentum indicator, meaning the signals are instant.
- Ranges between 0 and 100.
- Above 70 is considered overbought.
- Below 30 is considered oversold.
- Above or below 50 can also be used to determine price trend or support and resistance.
- RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
- Can be used in many different ways
Score
Let's take a look at the Relative Strength Index (RSI) of RTA Laboratuvarlari Biyolojik. The current rsi is 43.64. The current phase is Correction in bull market.
The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).
- Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
- Trending down: The RSI is trending down. -1
3.2 Stochastic Oscillator
- Leading momentum indicator, meaning the signals are instant.
- Used to determine overbought and oversold areas much like the RSI.
- Ranges between 0 and 100.
- Above 80 is considered overbought.
- Below 20 is considered oversold.
- Consists of two lines named K and D.
- K compares the highest high and lowest low on the selected price range.
- The D line is a moving average of the K line.
- Can be used to spot divergences
Score
Let's take a look at the Stochastic Oscillator of RTA Laboratuvarlari Biyolojik. The current phase is Oversold in bull market.
The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).
- STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
- STOCH < 20: The STOCH %K is below 20 and oversold. -2
- STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the RTA Laboratuvarlari Biyolojik price going up in the near term. +2
- Trending up: The STOCH %K is trending up. +1
3.3 Commodity Channel Index (CCI)
- Lagging or leading Momentum indicator
- When the CCI is above zero, the price is above the historical average
- When the CCI is below zero, the price is below the historical average
- Used for spotting trends
- If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
- If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend
Score
Let's take a look at the Commodity Channel Index (CCI) of RTA Laboratuvarlari Biyolojik. The current cci is -102.99171104.
The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).
- CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
3.4 Chande Momentum Oscillator (CMO)
- Lagging momentum indicator
- Ranges between +100 and -100
- Considered overbought above +50
- Considered oversold below -50
- It's possible to add a moving average that acts as a signal line
Score
Let's take a look at the Chande Momentum Oscillator (CMO) of RTA Laboratuvarlari Biyolojik. The current cmo is -26.8758277.
The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).
- CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
3.5 Williams %R
- Lagging momentum indicator
- Ranging between 0 and -100
- Above -20 is considered overbought
- Below -80 is considered oversold
- Is prone to give false signals
Score
Let's take a look at the Williams %R of RTA Laboratuvarlari Biyolojik. The current willr is -96.92982456.
The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).
- WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
4. Volatility Indicators
4.1 Bollinger Bands
- Lagging volatility indicator
- Uses 3 bands: one upper, one lower and one in the midd